AIMLogo.jpg
Hemispherx Presents New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 21, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University will present a research paper on January 21,...
TuftsCSDD-Logo-Color.jpg
Drug Developers Are Implementing New Strategies for Use of Comparator Drugs in Clinical Trials, According to Tufts Center for the Study of Drug Development
January 16, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 16, 2014) - Drug developers are aggressively implementing new strategies to improve their access to and use of comparator drugs, which are used in clinical trials to...
TuftsCSDD-Logo-Color.jpg
Drug Company Success Depends on New Development Paradigms, According to Tufts Center for the Study of Drug Development
January 07, 2014 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 7, 2014) - While many drug developers continue to improve clinical trial operational efficiency to increase the pace of new product introductions, their medium- and...
_Matrix_Registered_Logos_WhiteLogo-Transparency copy 2.png
Matrix Medical Network Annually Recognizes Nurse Practitioner Excellence With NP3 Award
December 12, 2013 11:03 ET | Matrix Medical Network
SCOTTSDALE, Ariz., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Matrix Medical Network, a national leader in prospective medical assessment services for Medicare Advantage (MA) plan members and one of the...
TuftsCSDD-Logo-Color.jpg
Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development
November 14, 2013 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 14, 2013) - The pharmaceutical industry, especially Big Pharma, has dramatically shifted its R&D focus from its historical concentration on small molecule drugs...
TuftsCSDD-Logo-Color.jpg
Drug Sponsors and Their External Service Partners Say Adjusting Relationship Models Offers a Path to Greater Performance and Efficiency, According to Tufts Center for the Study of Drug Development
October 08, 2013 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Oct 8, 2013) - While drug sponsor use of strategic relationships with contract service providers has increased dramatically during the past five years, improvements in...
TuftsCSDD-Logo-Color.jpg
Clinical Study Failures Vary Widely by Phase of Study and Therapeutic Class, According to the Tufts Center for the Study of Drug Development
September 10, 2013 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 10, 2013) - While lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues dominate as the reason for Phase II...
OPEN MINDS logo
How To Leverage New Technologies To Succeed In A Consumer-Centric Healthcare Environment -- Topic Of New Executive Web Briefing From Netsmart & OPEN MINDS
August 16, 2013 17:06 ET | Open Minds
GETTYSBURG, Pa., Aug. 16, 2013 (GLOBE NEWSWIRE) -- Free Registration Link: http://www.openminds.com/events/webinar-082113-clinicalit.htm OPEN MINDS and Netsmart have announced a new...
OM_Logo-4c.jpg
CoCENTRIX to Present Clinical Best Practices for Behavioral Health Providers in "Discharge Planning: Best Practices for a Safe & Accountable Transition of Care"
August 15, 2013 17:20 ET | Open Minds
GETTYSBURG, Pa., Aug. 15, 2013 (GLOBE NEWSWIRE) -- OPEN MINDS and CoCENTRIX have announced a new executive web briefing specifically designed to help behavioral health and human service provider...
TuftsCSDD-Logo-Color.jpg
Drug Industry Leaders See Collaboration as Key to Greater Productivity, According to Tufts Center for the Study of Drug Development
August 13, 2013 09:00 ET | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 13, 2013) -  Responding to a widely shared need to improve the probability of R&D success, leaders from the research-based drug industry, recently convened by...